Genmab A/S (GMAB) Stock Forecast & Price Target
Score
Genmab A/S price target
| GMAB | |
|---|---|
| Low | $32.00 |
| Median | $42.50 |
| High | $70.00 |
| Upside vs current price | -17.3% |
The median target of $42.50 is -17.3% versus the current GMAB price of $51.37.
Genmab A/S analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 10 |
| Hold | 2 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
13 analysts cover GMAB.
Genmab A/S EPS and revenue estimates
GMAB shows the next fiscal years with at least three analysts: 2026 EPS $1.25, 2027 EPS $1.63. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $1.25 | $4.47B |
| 2027 | $1.63 | $5.41B |
Is Genmab A/S a buy or sell?
Of the 13 analysts covering Genmab A/S, 11 rate it a buy (1 strong buy and 10 buy), 2 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The GMAB consensus label is Buy, beside 11 buy-side ratings and 0 sell-side ratings.
The median target of $42.50 implies -17.3% versus the current price of $51.37.
Those 13 ratings on GMAB are a headcount, and the label on file is Buy.
Reading the Genmab A/S forecast
The GMAB target range is wide: $32.00 at the low end, $42.50 in the middle, and $70.00 at the top.
Set next to the $51.37 GMAB quote, that median is -17.3%.
Ratings on the Genmab A/S cluster: 11 of 13 analysts are on the buy side, 2 are at hold, and 0 are on the sell side, and the published consensus is Buy.
Recent GMAB revisions are two-sided: 1 upgrades and 0 downgrades.
The average GMAB target over the last month is $61.00, above the $55.50 average of the last quarter.
Only 8 desks have a fresh median target on GMAB, so the range rests on a short list.
Genmab A/S forecast questions
What is the GMAB price target?
The published range for GMAB is $32.00 to $70.00, with a median target of $42.50. That median is -17.3% versus the current price of $51.37.
Is Genmab A/S a buy or sell?
Of the 13 analysts covering Genmab A/S, 11 rate it a buy, 2 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the GMAB headcount is 11 buy, 2 hold, and 0 sell.
What is the EPS estimate for Genmab A/S?
Analyst EPS estimates for Genmab A/S: 2026 $1.25, 2027 $1.63.
What is the revenue estimate for Genmab A/S?
Analyst revenue estimates for Genmab A/S: 2026 $4.47B, 2027 $5.41B.
How many analysts cover GMAB?
13 analysts cover GMAB. Their consensus on GMAB is Buy, across those 13.